A COVID–19 kapcsán tapasztalható jelenség a szérummájenzim-aktivitásnak a laboratóriumi vizsgálat során észlelt emelkedése. Ezen változások hátterében feltehetően három patomechanizmus áll: 1) a SARS-CoV-2 direkt citotoxikus és indirekt sejtszintű és szisztémás következményei, 2) a COVID–19-ben alkalmazott gyógyszeres kezeléseknek (remdesivir, favipiravir, tocilizumab, baricitinib, szisztémás kortikoszteroid) a farmakológiai hatásai, illetve 3) a betegekben korábban fennálló krónikus májbetegség(ek) progressziója. A májenzim-emelkedés kiváltó okának differenciáldiagnosztikája és a terápiával kapcsolatos döntéshozatal kihívást jelenthet a klinikus számára, mivel a nem megfelelő kezelés a COVID–19 vagy a májkárosodás progresszióját okozhatja. A jelen összefoglaló a COVID–19-betegeket ellátó klinikusok számára kíván alapvető támpontot nyújtani a helyes döntéshez. Orv Hetil. 2022; 163(36): 1415–1421.
World Health Organization. Weekly epidemiological update on COVID-19 – 1 February 2022. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-february-2022 [accessed: 01. 02. 2022].
Epidemiological statistics. [Epidemiológiai statisztika.] Available from: https://koronavirus.gov.hu/ [accessed: 01. 02. 2022]. [Hungarian]
Baborczy B, Bartókné TR, Bíró K, et al. Hungarian coronavirus guideline. [Magyar Koronavírus Kézikönyv.] Emberi Erőforrások Minisztériuma, Budapest, 2021. [Hungarian]
Hsu JY, Mao YC, Liu PY, et al. Pharmacology and adverse events of emergency use authorized medication in moderate to severe COVID-19. Pharmaceuticals 2021; 14: 955.
Bhimraj A, Morgan RL, Shumaker AH, et al. IDSA Guidelines on the treatment and management of patients with COVID-19. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ [accessed: 08. 03. 2022].
Delgado A, Stewart S, Urroz M, et al. Characterisation of drug-induced liver injury in patients with COVID-19 detected by a proactive pharmacovigilance program from laboratory signals. J Clin Med. 2021; 10: 4432.
Larson AM. Drug-induced liver injury. Available from: https://www.uptodate.com/contents/drug-induced-liver-injury [accessed: 08. 03. 2022].
Ortiz GX, Lenhart G, Becker MW, et al. Drug-induced liver injury and COVID-19: a review for clinical practice. World J Hepatol. 2021; 13: 1143–1153.
Bertolini A, van de Peppel IP, Bodewes F, et al. Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis. Hepatology 2020; 72: 1864–1872.
Liemarto AK, Budiono BP, Chionardes MA, et al. Liver abscess with necrosis in post COVID-19: a case report. Ann Med Surg. 2021; 72: 103107.
Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for ACTEMRA® (tocilizumab). Available from: https://www.fda.gov/media/150321/download [accessed: 08. 03. 2022].
Muhović D, Bojović J, Bulatović A, et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int. 2020; 40: 1901–1905.
Campbell C, Andersson MI, Ansari MA, et al. Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era. Front Med. 2021; 8: 706482.
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015; 17: 14.
Sodeifian F, Seyedalhosseini ZS, Kian N, et al. Drug-induced liver injury in COVID-19 patients: a systematic review. Front Med. 2021; 8: 731436.
Lakatos B, Gopcsa L, Gondos E, et al. Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectiology. [Citokinellenes terápia az új típusú koronavírus okozta megbetegedés (COVID–19) kezelésében – tocilizumab elsőként való alkalmazása egy hazai infektológiai osztályon.] Orv Hetil. 2020; 161: 1070–1077. [Hungarian]
Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: an A–Z literature review. Dig Liver Dis. 2021; 53: 146–152.
Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases 2022; 10: 1140–1163.
Lexicomp. Baricitinib: drug information. Available from: https://www.uptodate.com/contents/baricitinib-drug-information [accessed: 08. 03. 2022].
Lexicomp. Favipiravir (United States: Not commercially available; refer to ‘Prescribing and Access Restrictions’ field): drug information. Available from: https://www.uptodate.com/contents/favipiravir-united-states-not-commercially-available-refer-to-prescribing-and-access-restrictions-drug-information [accessed: 08. 03. 2022].
Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020; 6: 1192–1198.
Kaur RJ, Charan J, Dutta S, et al. Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database. Infect Drug Resist. 2020; 13: 4427–4438.
Kumar P, Kulkarni A, Sharma M, et al. Favipiravir-induced liver injury in patients with coronavirus disease 2019. J Clin Transl Hepatol. 2021; 9: 276–278.
European Medicines Agency. RoActrema. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra [accessed: 08. 03. 2022].
Hoofnagle JH. (ed.) LiverTox. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012.
Fábián Á, László I, Juhász M, et al. Pharmacological options in treating SARS-CoV-2 infection/COVID-19. [Farmakoterápiás lehetőségek SARS-CoV-2-fertőzés/COVID-19-betegség esetén.] Orv Hetil. 2020; 161: 685-688.
Szekanecz Z, Bogos K, Constantin T, et al. Antiviral and anti-inflammatory therapies in COVID–19. [Antivirális és gyulladásellenes kezelési lehetőségek COVID–19-ben.] Orv Hetil. 2021; 162: 643–651. [Hungarian]